{"product_id":"deakos-ausilium-bau-100-g-ausilium","title":"Ausilium Bau 100 G Ausilium","description":"\u003ch2 style=\"font-size: medium;\"\u003eAUSILIUM BAU 100 G AUSILIUM\u003c\/h2\u003e\u003cbr\u003e\u003ch3 style=\"font-size: medium;\"\u003e\u003c\/h3\u003e\u003cbr\u003e\u003ch3 style=\"font-size: medium;\"\u003eAUSILIUM BAU\u003c\/h3\u003e Suplemento alimentar em pó para cães que contribui para proteger as vias urinárias.\u003cbr\u003e Indicado como remédio complementar em cistites e outras infeções das vias urinárias, é particularmente eficaz em caso de Escherichia coli, Klebsiella, Enterococcus faecalis, Streptococcus, Staphylococcus, Proteus, Pseudomonas e outras bactérias fimbriadas. Ao contrário do que acontece com a terapia antibiótica, as bactérias não são mortas, mas eliminadas de forma mecânica, arrastadas para fora com o fluxo da urina. Isso permite não danificar a flora bacteriana fisiológica, valiosa aliada da saúde do animal.\u003cbr\u003e AUSILIUM MIAO pode ser administrado tanto durante as fases agudas (em associação com as terapias específicas indicadas pelo veterinário responsável) como nas formas recorrentes ou recidivantes (sozinho ou em associação com as dietas específicas recomendadas pelo veterinário). Além disso, pode ser utilizado também na fase de prevenção e manutenção.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eIngredientes\u003c\/b\u003e\u003cbr\u003e Maltodextrina, Farinha de fígado de porco, D-Mannose.\u003cbr\u003e Produtos naturais botanicamente definidos: extrato de Morinda citrifolia L. 70.000 mg.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eModo de uso\u003c\/b\u003e\u003cbr\u003e Misturar o pó à ração habitual de comida húmida de acordo com a seguinte dosagem diária: \u003cbr\u003e - até 10 kg de peso: 2 medidas por dia, em duas administrações, para um total de 3 g;\u003cbr\u003e - de 10 a 20 kg de peso: 4 medidas por dia, em duas administrações, para um total de 6 g;\u003cbr\u003e - acima de 20 kg de peso: 6 medidas por dia, em duas administrações, para um total de 9 g.\u003cbr\u003e Na fase de prevenção e manutenção será suficiente metade da dosagem.\u003cbr\u003e Em caso de alimentação exclusivamente seca, humedecer ligeiramente o alimento para permitir uma boa adesividade do pó e a sua completa ingestão.\u003cbr\u003e É aconselhável realizar um ciclo de administração de 10-15 dias, eventualmente repetível a critério do veterinário.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eAvisos\u003c\/b\u003e\u003cbr\u003e Produto apenas para uso veterinário. Manter fora do alcance das crianças.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eConservação\u003c\/b\u003e\u003cbr\u003e Conservar em local seco e protegido da luz.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eFormato\u003c\/b\u003e\u003cbr\u003e Embalagem de 100 g.\u003cbr\u003e \u003cbr\u003e \u003cb\u003eCód.\u003c\/b\u003e PT267\u003cbr\u003e \u003cbr\u003e \u003cu\u003eBibliografia\u003c\/u\u003e:\u003cbr\u003e 1. Abgottspon D, Rabbani S, Herold J, Jiang X, Ernst B. \u003ci\u003eFimH antagonists for the oral treatment of urinary tract infection: from design and synthesis to in vitro and in vivo evaluation\u003c\/i\u003e. Klein J Med Chem Dec 2010;53:8627-41.\u003cbr\u003e 2. Akihisa T, Matsumoto K, Tokuda H. \u003ci\u003eAnti-inflmmatory and potential cancer chemopreventive constituents of the fruits of Morinda citrifolia (Noni)\u003c\/i\u003e. J Nat Prod 2007;70:754-7.\u003cbr\u003e 3. Alitheen NB, Manaf AA, Yeap SK. \u003ci\u003eImmunomodulatory effects of Damnacanthal isolated from roots of Morinda elliptica\u003c\/i\u003e. Pharm Biol 2010;48:446-52.\u003cbr\u003e 4. Altarac S, Papes D. \u003ci\u003eUse of d-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women\u003c\/i\u003e. BJU Int 2014;113:9-10.\u003cbr\u003e 5. \u003ci\u003eAmerican Chemical Society. Noni plant may yield new drugs to fight tuberculosis\u003c\/i\u003e. Press Release at the 2000 International Chemical Congress of Pacific Basin Societies.\u003cbr\u003e 6. Crepin S, Houle S, Carbanneau ME', Mourez M, Harel J, Dozois CM. \u003ci\u003eDecreased expression of type 1 fibriae by a pst mutant of uropathogenic Escherichia urinary tract infection: contribution to intracellular biofilm development\u003c\/i\u003e. Virulence 2010;1:333-7.\u003cbr\u003e 7. Cusumano CK, Pinkner JS, Han Z, Handerson JP, Croweley JR, Hultgren SJ. \u003ci\u003eTreatment and prevention of urinary tract infection with orally active FimH inhibitors\u003c\/i\u003e. Sci Transl Med Nov 2011;3:109-15.\u003cbr\u003e 8. Gupta RK, Banerjee A, Pathak S. \u003ci\u003eInduction of mitochondrial-mediated apoptosis by Morinda citrifolia (Noni) in human cervical cancer cells\u003c\/i\u003e. Asian Pac J Cancer Prev 2013;14:237-42.\u003cbr\u003e 9. Gupta RK, Patel AK. \u003ci\u003eDo the health claims made for Morinda citrifolia (Noni) harmonize with current scientific knowledge and evaluation of its biological effects\u003c\/i\u003e. Asian Pac J Canc Prev 2013;14:147-49.\u003cbr\u003e 10. Heinicke R. \u003ci\u003eThe Xeronine system: a new cellular mechanism that explains the health promoting action of NONI and Bromelina\u003c\/i\u003e. Direct Source Pub 2001.\u003cbr\u003e 11. Jiang X, Abgottspon D, Kleeb S, Rabbani S, Scharenberg M, Wittwer M et al. \u003ci\u003eAntiadhesion therapy for urinary tract infections--a balanced PK\/PD profile proved to be key for success\u003c\/i\u003e. J Med Chem 2012;55:4700-13.\u003cbr\u003e 12. Kranjcec B, Papes D, Altarac S. \u003ci\u003eD-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial\u003c\/i\u003e. World J Urol 2013;32:79-84.\u003cbr\u003e 13. Nava CM, Ricciardo G, Valieri M. \u003ci\u003eTrattamento e prevenzione delle recidive delle vaginiti\u003c\/i\u003e. Medicinae Doctor 2013 numero 8.\u003cbr\u003e 14. Pawlus AD, Su BN, Keller WJ. \u003ci\u003eAn anthraquinone with potent quinone reductase-inducing activity and other constituents of the fruits of Morinda citrifolia (Noni)\u003c\/i\u003e. J Nat Prod 2005;68:1720-2.\u003cbr\u003e 15. Porru D, Parmigiani A, Tinelli C, Barletta D, Choussos D, Di Franco C, Bobbi V, Bassi S, Miller O, Gardella B, Nappi RE, Spinillo A and Rovereto B. \u003ci\u003eOral D-mannose in recurrent urinary tract infections in women: A pilot study\u003c\/i\u003e. J Clin Urol 2014; 20 (10) 1–6.\u003cbr\u003e 16. Pratt LA, Kolter R. \u003ci\u003eGenetic analysis of Escherichia coli biofilm formation: roles of flagellar motility, chemotaxis and type 1 pili\u003c\/i\u003e. Mol Microbiol 1998;30:285-93.\u003cbr\u003e 17. Reid G, Sobel JD. \u003ci\u003eBacterial adherence in the pathogenesis of urinary tract infection: a review\u003c\/i\u003e. Clin Infect Dis 1987;9:470-87.\u003cbr\u003e 18. Sharon N. \u003ci\u003eCarbohydrates as future anti-adhesion drugs for infectious diseases\u003c\/i\u003e. Biochim Biophys Acta 2006;1760:527-37.\u003cbr\u003e 19. Umezawa K. \u003ci\u003eIsolation of 1-methoxy-2-formyl-3-hydroxyanthraquinone from M citrifolia and neoplasminhibitors containing the same\u003c\/i\u003e. Japan Kokai Tokyo Koho JP 1992;87:736(94-87, 736).\u003cbr\u003e 20. Wellens A, Garofalo C, Nguyen H, Van Gerven N, Bouckaert J. \u003ci\u003eIntervening with urinary tract infections using anti-adhesives based on crystal structure of the FimH-oligomannose-3 complex\u003c\/i\u003e. PLoS one 2008;3:e2040.\u003cbr\u003e","brand":"Ausilium","offers":[{"title":"Default Title","offer_id":50350358397220,"sku":"925632731","price":19.01,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0915\/8934\/5572\/files\/925632731_P.jpg?v=1738806383","url":"https:\/\/bfarma.it\/pt\/products\/deakos-ausilium-bau-100-g-ausilium","provider":"BFarma.it","version":"1.0","type":"link"}